Database

This repeated-measures dose-dependent study (n=19) investigates DMT's subjective and neural dynamics under naturalistic conditions. Participants received 20mg or 40mg doses of freebase DMT in a blinded, counterbalanced design, with EEG data and time-resolved subjective measures collected. The 40mg dose produced more intense visual hallucinations and emotional responses. Neural analyses revealed alpha power and permutation entropy were most associated with subjective experiences, whereas lempel-ziv complexity was less predictive, challenging prior assumptions about its role in psychedelic states.

This phenomenological study (n=23) investigates DMT-induced immersive experiences and encounters with autonomous presences during fMRI scanning. Using micro-phenomenological interviews, it identifies structural features and temporal dynamics of DMT experiences, highlighting layered sensory, spatial, self-related, and social effects that extend beyond ego dissolution or mystical experiences.

This re-analysis of an RCT (n=51) investigates the effects of psilocybin-assisted therapy on empathy in depressed patients. Participants received either a single psilocybin dose (15mg/70kg) or placebo within a 4-week psychological support programme. Psilocybin significantly improved emotional empathy, particularly towards positive stimuli, for up to two weeks compared to placebo.

This re-analysis of the COMPASS Phase IIb trial (n=233) investigates the relationships between psilocybin dose, psychedelic experiences, and therapeutic outcomes in treatment-resistant depression. Participants received a single dose of 25, 10, or 1 mg of psilocybin (COMP360) with psychological support. Higher doses produced stronger psychedelic effects, and reductions in depression (MADRS scores) at Week 3 correlated most strongly with dimensions of Oceanic Boundlessness (r = −0.508), Visual Restructuralization (r = −0.516), and Emotional Breakthrough Inventory (r = −0.637). Findings suggest the quality and intensity of psychedelic experiences mediate therapeutic outcomes and support dose-response mechanisms.

This re-analysis of a single-blind, fixed-order trial (n=28) investigates the effects of a single high-dose psilocybin (25 mg) on personality traits in psychedelic-naïve healthy volunteers. It finds significant reductions in neuroticism one month post-administration, moderated by subjective experience meaningfulness and ego dissolution, suggesting psilocybin catalyses lasting personality changes with therapeutic potential.

This systematic review (2024; s=9) of healthcare workers' attitudes and knowledge about psychedelic-assisted therapy for patients with serious illness finds polarized views, with most acknowledging potential benefits but desiring further education and a stronger evidence base.

This review (2024) examines the recent approval by the Australian Therapeutic Goods Administration (TGA) of psilocybin for treatment-resistant depression (TRD) and MDMA for PTSD, effective 1 July 2023. It highlights the campaign led by Mind Medicine Australia and supported by leading researchers and institutions, as well as implications for future approvals and psychedelic drug development pathways.

This double-blind, randomized, placebo-controlled, crossover study (n=22) investigates the dose-dependent effects and pharmacokinetics of continuous intravenous DMT infusions over 120 minutes. It finds dose-proportional pharmacokinetics, a rapid onset of subjective effects that plateaus at 30 minutes, and a ceiling effect for positive effects at 1.8 mg/min. Higher doses (2.4 mg/min) induce anxiety and ego dissolution. Moderate acute tolerance and successful self-titration for desired effects were observed.

This systematic review (s=45) on psychedelic-assisted psychotherapy for mental disorders finds that psychological interventions are reported with low completeness and high heterogeneity. It also finds that MDMA studies are more homogeneous, with greater procedural detail.

This systematic review (2024) and meta-analysis (s=44) finds that medium/high doses of LSD yield higher ratings of visionary restructuralisation than psilocybin. It also reports that psychedelics strengthen between-network functional connectivity and diminish within-network connectivity, and that LSD induces more inositol phosphate formation at the 5-HT2A receptor than DMT or psilocin, while receptor selectivity differences remain negligible.